Sign in

    Chen Yang

    Vice President and Quantitative Analyst at Bank of America

    Chen Yang is a Vice President and Quantitative Analyst at Bank of America, specializing in quantitative research and risk analytics within the financial services sector. He is known for his expertise in developing sophisticated models for asset valuation, portfolio optimization, and risk management, supporting coverage of major institutional clients and global banking operations. Beginning his career after earning a master’s degree in statistics from the University of Chicago, Yang joined Bank of America in the early 2020s and has since contributed to multiple cross-functional teams, earning recognition for analytical rigor and data-driven performance improvement. He holds advanced professional credentials in quantitative finance and is registered with FINRA, demonstrating a commitment to both regulatory standards and ongoing professional development.

    Chen Yang's questions to Neumora Therapeutics (NMRA) leadership

    Chen Yang's questions to Neumora Therapeutics (NMRA) leadership • Q3 2024

    Question

    Chen Yang from Bank of America asked for confirmation on whether the last patient had been enrolled for the KOASTAL-1 study and, if so, the specific date of enrollment.

    Answer

    Robert Lenz, Head of Research and Development, did not comment on specific enrollment details or timelines. He reiterated the company's confidence in delivering the top-line results for KOASTAL-1 around the end of the year and stated that enrollment details would be shared with the results.

    Ask Fintool Equity Research AI

    Chen Yang's questions to CureVac (CVAC) leadership

    Chen Yang's questions to CureVac (CVAC) leadership • Q3 2024

    Question

    Chen Yang inquired about CureVac's interest in business development opportunities outside its core mRNA expertise and requested an update on the company's ongoing patent litigation.

    Answer

    CEO Alexander Zehnder stated that CureVac remains focused on oncology and infectious diseases but is open to opportunities that strengthen its portfolio within these areas. Regarding litigation, he highlighted the upcoming U.S. court case scheduled for March 2025 as the next key event.

    Ask Fintool Equity Research AI

    Chen Yang's questions to CureVac (CVAC) leadership • Q4 2023

    Question

    Chen Yang from Bank of America inquired about the regulatory pathway and potential timeline for the glioblastoma program if successful. He also asked how the company prioritizes its various early-stage cancer programs given its cash position and what kind of strategic deals might be pursued by the incoming Chief Business Officer.

    Answer

    CDO Myriam Mendila clarified that the glioblastoma trial is a proof-of-principle study and not currently planned for further development unless highly compelling efficacy data emerges. CEO Alexander Zehnder stated that the new CBO will focus on partnerships in oncology, unpartnered infectious disease assets, and molecular therapies.

    Ask Fintool Equity Research AI

    Chen Yang's questions to CureVac (CVAC) leadership • Q4 2023

    Question

    Chen Yang of Bank of America inquired about the potential regulatory pathway and timeline for the glioblastoma program if it proves successful. He also asked how CureVac prioritizes its early-stage cancer programs given its cash runway and what kind of strategic deals might be pursued by the incoming Chief Business Officer.

    Answer

    CDO Myriam Mendila reiterated that the glioblastoma trial is a proof-of-principle study and not planned for further development unless highly compelling efficacy data emerges. She noted program prioritization will occur after more data is available. CEO Alexander Zehnder stated that the new CBO will focus on partnerships for oncology assets, unpartnered infectious disease programs, and molecular therapies.

    Ask Fintool Equity Research AI

    Chen Yang's questions to CureVac (CVAC) leadership • Q3 2023

    Question

    Asked about the appeal timeline for the patent case and its impact on damages, the path to a pivotal study for the cancer vaccine, and the timeline for new oncology programs.

    Answer

    The company explained that in Germany, damages assessment would run parallel to an appeal. They clarified that the current oncology programs are proof-of-concept, and the focus for future pivotal trials will be on next-generation candidates from their advanced antigen discovery platform, with a new Phase I trial planned within 18 months.

    Ask Fintool Equity Research AI

    Chen Yang's questions to Amylyx Pharmaceuticals (AMLX) leadership

    Chen Yang's questions to Amylyx Pharmaceuticals (AMLX) leadership • Q3 2024

    Question

    Chen Yang of Bank of America inquired about the Phase III trial design for avexitide in PBH, asking what factors beyond the previous Eiger agreement are being considered and if there's potential for a readout earlier than 2026.

    Answer

    Dr. Camille Bedrosian, Chief Medical Officer, confirmed the trial design is being refined based on prior FDA discussions. She reiterated key elements: a 90mg dose, a primary composite endpoint of Level 2 and 3 hypoglycemia events, and a proposed 90-participant, 12-week study. She affirmed the timeline, expecting trial initiation in Q1 2025 with top-line data anticipated in 2026.

    Ask Fintool Equity Research AI